TG Therapeutics (TGTX) AI Stock Analysis

• Market Cap: $5.97B
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): 154.1
• Beta (1Y): 1.64
• Revenue Growth: 33.54%
• EPS Growth: -6.13%
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 158,755,040
• 10 Day Avg. Volume: 1,475,745
• 30 Day Avg. Volume: 1,547,174
• PEG Ratio: 2.28
• Price to Book (P/B): 23.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -99.00
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 4.63
• Enterprise Value/Gross Profit: 18.20
• Enterprise Value/Ebitda: 26.28
• 1Y Price Target: $38.00
• Price Target Upside: 4.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 68 Neutral
• Price Target: $40.00 ▲(9.50%Upside)

TG Therapeutics demonstrates strong financial recovery and promising growth potential, as highlighted in the earnings call with increased sales and revenue guidance. However, the high P/E ratio and ongoing cash flow challenges present valuation concerns and liquidity risks.

Positive Factors

Commercial Performance

Record patient enrollments were observed despite headwinds and the recent product launch of a competitor, indicating minimal-to-no competitive impact.

Market Expansion

Briumvi is now commercially available in additional countries in the EU, UK, and Switzerland, which could translate into incrementally larger royalty revenue in the quarters ahead.

Revenue Growth

The company's revenue growth justifies additional pipeline investments.

Negative Factors

Competition

Ocrevus Zunovo still remains bigger risk to Briumvi growth.

Development Challenges

TG’s subq option remains behind in development, though less frequent dosing may be beneficial.

Market Perception

Analyst reiterates Underperform and $11 price objective on, in their view, an overvalued long-term market opportunity for Briumvi with key challenges to competitive pillars ahead.

TG Therapeutics Business Overview & Revenue Model

Company Description

TG Therapeutics (TGTX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, NY, and operates within the healthcare sector, primarily targeting hematologic cancers and other B-cell related disorders. TG Therapeutics' core products include therapies aimed at transforming the treatment landscape for patients with these conditions.

How the Company Makes Money

TG Therapeutics generates revenue through the sales of its pharmaceutical products, primarily focusing on innovative treatments for B-cell malignancies and autoimmune diseases. The company's revenue model is centered around the commercialization of its core products, which are developed through extensive research and clinical trials. Key revenue streams include product sales upon obtaining regulatory approval and entering the market. Additionally, TG Therapeutics may engage in strategic partnerships or collaborations with other pharmaceutical companies to enhance the development and distribution of its products, thereby contributing to its earnings. These partnerships may also involve licensing agreements, milestone payments, and royalties, which can provide additional financial support and revenue opportunities.

TG Therapeutics Financial Statement Overview

Summary

TG Therapeutics shows a strong recovery trajectory with significant revenue and profit growth, alongside improved balance sheet metrics. However, the continued negative operating cash flow and historical financial instability present areas of concern.

Income Statement

TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.

Balance Sheet

The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.

Cash Flow

The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	329.00M	233.66M	2.79M	6.69M	152.00K
Gross Profit	290.52M	219.11M	2.52M	5.90M	-222.00K
EBITDA	49.90M	26.10M	-187.63M	-341.97M	-272.68M
Net Income	23.38M	12.67M	-203.83M	-355.55M	-285.88M
Balance Sheet
Total Assets	577.69M	329.59M	193.57M	379.63M	625.64M
Cash, Cash Equivalents and Short-Term Investments	311.00M	217.51M	174.08M	350.30M	605.43M
Total Debt	254.38M	110.80M	83.06M	79.05M	41.98M
Total Liabilities	355.33M	169.09M	134.99M	142.48M	106.29M
Stockholders Equity	222.36M	160.50M	-1.53B	-1.33B	519.35M
Cash Flow
Free Cash Flow	-40.56M	-31.41M	-176.18M	-296.04M	-214.86M
Operating Cash Flow	-40.52M	-31.41M	-176.17M	-295.63M	-214.51M
Investing Cash Flow	-1.04M	-50.65M	-20.01M	-332.00K	-24.51M
Financing Cash Flow	128.53M	72.70M	-391.00K	41.42M	679.83M

TG Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 36.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 36.53 is below the 20-day moving average (MA) of 37.25, below the 50-day MA of 36.54, and above the 200-day MA of 33.65, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 22.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.

TG Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAZZ	75 Outperform	$7.14B	15.91	12.25%	―	5.76%	49.58%
TGTX	68 Neutral	$5.97B	154.10	19.70%	―	33.54%	-6.13%
RYTM	62 Neutral	$5.77B	―	-418.97%	―	48.88%	39.30%
IONS	58 Neutral	$6.75B	―	-118.53%	―	-7.65%	-11.81%
AXSM	54 Neutral	$5.24B	―	-282.16%	―	72.16%	9.65%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
NUVL	43 Neutral	$5.78B	―	-35.69%	―	―	-81.09%

TG Therapeutics Corporate Events

TG Therapeutics Approves Key Proposals at Annual Meeting

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.